• PlantX has opened its first United States brick and mortar store in the Hillcrest neighborhood of San Diego, although the company’s earlier acquisition of New Deli, a vegan marketplace opened by Chef Matthew Kenney, resulted in a rebranding of their Venice, California New Deli location as XMarket
• The partnership between PlantX and Kenney reflects a mission to educate consumers and the public about living a plant-based/vegan lifestyle by offering educational resources in the form of blogs, podcasts, and YouTube videos
• PlantX features products ranging from food, beverages, pets, personal hygiene, and more, and the company’s XMarket locations also offer local delivery options via Uber Eats
• The company is now working on opening XMarket locations in Hudson’s Bar stores in Toronto and Ottawa, along with an opening in Tel Aviv, Israel

Described as the “vegan Amazon,” PlantX Life (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) has opened its first United States brick and mortar establishment, XMarket, in San Diego’s Hillcrest neighborhood, following an earlier rebranding of an acquired location in Venice, California as XMarket. According to Alex Hoffman, CMO of PlantX, the company’s next location will be in Tel Aviv, Israel, followed by two locations opening up inside Hudson’s Bay stores in Ottawa (Rideau), and Toronto (Yorkdale). “A few other locations are on our radar, but nothing finalized yet,” Hoffman added. The company plans to take plant-based and vegan living worldwide – providing resources and educational materials to those interested in the benefits. According to Kenney, the goal of the partnership with Plantx is to “educate and provide more people access to a plant-based lifestyle”, adding that “Along with our retail and ecommerce initiatives, we are committed to investing in and developing innovative products that bring a sustainable and healthful change to the culinary landscape” (https://ibn.fm/rXHYU). PlantX, much like Kenney, aims to redefine the plant-based community through e-commerce, becoming a trusted name for people living plant-based lives. As an e-commerce marketplace, PlantX offers:

• An array of plant-based grocery items
• Meal delivery with recipes created by renowned plant-based chefs from around the world
• Plant shop – delivers to homes across the United States and Canada
• Easy to follow weekly plant-based recipes
• Partnership with prominent vegan/plant-based community figures
• A community of like-minded individuals

As for XMarket, the shelves are lined with a large selection of vegan and plant-based products. The store also offers local vegan business products, including Kula Ice Cream, Tracy’s Real Food, and San Diego Tempeh soy-free proteins. There is also an open-air vegan café that serves Unity Coffee cappuccinos, oat milk lattes, and cups of steeped Brandywine Coffee Roasters teas. These drinks pair nicely with the pastries from Pan el Barro, The Gluten Free Baking Co., and Yvonne’s Vegan Kitchen. PlantX and XMarket are devoted to providing patrons with the proper educational materials – allowing them to determine if a plant-based/vegan lifestyle is right for them. XMarket offers visiting patrons educational literature that has been included around the market space, including recipe cards, plant care notes, and prominently displayed nutritional information. The staff at the market has also completed training by nutritionist Kelly Irwin and is prepared to answer any questions the public may have while shopping. For more information, visit the company’s websites at www.PlantX.com, www.PlantX.ca, and https://investor.plantx.com/ and view PlantX for Plant-Based Investors. NOTE TO INVESTORS: The latest news and updates relating to PLTXF are available in the company’s newsroom at https://ibn.fm/PLTXF

• International cannabis cultivator, manufacturer, and distributor of plant-based lifestyle and wellness brands Flora Growth Corp. is steadily building a worldwide pipeline for downstream cannabis brands using its Colombian cultivation facilities and a growing list of trade partners
• Flora Growth recently announced multiple distribution and e-commerce marketplace agreements that will see its two leading skincare brands, MIND Naturals and Awe (Ô), distributed via GlossWire and Showfields
• The company also expects its Colombian on-site CBD extraction facility to come online as well as complete the first harvests of its high-THC psychoactive cultivars later in the month
• Flora Growth achieved Good Agricultural and Collection Practices (“GACP”) certification from the international medical cannabis standard-setter Control Union Medical Cannabis Standard (“CUMCS”) last month, which paves the way for international sales

A leading global cannabis cultivator and manufacturer of products and brands in CPG, fashion, food, and inhalation technology Flora Growth (NASDAQ: FLGC) is building an international pipeline for downstream cannabis products that begins with its cultivation facilities in Colombia’s ideal climate and ends with commercial outlets in nations ranging across the Americas, to the European Union, all the way around the world to Australia. The company announced an e-commerce agreement with SHOWFIELDS on Oct. 27, with GlossWire’s digital beauty marketplace Oct. 28 (https://ibn.fm/7Z3KI), and certification by international medical cannabis standards setter Control Union Medical Cannabis Standard (“CUMCS”) on Oct. 25 (https://ibn.fm/7VpGw). Flora Growth is preparing to fire up operation of its new onsite cannabis extraction facility in mid-November, located on-site at the company’s 100-hectare (247 acres) Cosechemos cultivation base in central Colombia. This development will complement its operational Flora Labs facility located in Bogotá that boasts a modern 16,000-square-ft manufacturing footprint and holds multiple GMP certifications with a diversified portfolio with over 190 products and 63 OTC products registered and licensed with INVIMA (FDA-equivalent in Colombia). Recent regulatory changes enacted by Colombia’s government have made it possible for companies such as Flora Growth to export dried cannabis flower and extracts used in pharmaceuticals and nutraceuticals in the food, beverage, cosmetics, and textiles markets without running afoul of the country’s drug interdiction efforts. Cannabis derivatives in the pharmaceutical and nutraceutical markets have gained acceptance worldwide in recent years, as well as the push towards legalization for adult-use in many jurisdictions around the world. Prohibition Partners’ own predictive outlook states the United Kingdom’s cannabis sector will see revenues growing to as much as $4.3 billion, North America’s to $47.3 billion, and the larger international market’s to $103.9 billion by 2024, showcasing the explosive expectations of international demand (https://ibn.fm/maOvd). Flora Growth’s deal with SHOWFIELDS and GlossWire will launch sales of Flora’s two skincare brands, MIND Naturals and Awe (Ô) and is expected to greatly enhance brand awareness in the United States. The marketplaces feature e-commerce interaction over “a highly curated mix of emerging and established brands that are making an impact in the beauty and grooming spaces,” according to the GlossWire announcement. “This unique intersection of tech and beauty allows for discovery, storytelling, and a deeper understanding of the customer,” Flora Growth President and CEO Luis Merchan stated, highlighting new emerging responsiveness to consumer trends and feedback. Flora reports it is achieving plant yields 40 to 60 percent higher than the company originally expected at its Cosechemos site and that it expects to harvest an initial crop of high-tetrahydrocannabinol (“THC”) psychoactive plant cultivars this month. The company is working on the pre-audit process for gaining good manufacturing practice (“GMP”) status with the European Union for the Cosechemos facility’s products and has also partnered with Hoshi International Inc. to provide another pathway to Europe. “The primary focus at Cosechemos this year has been optimizing and scaling our cultivation and processing activities while working closely with regulatory bodies and agencies to be granted our GACP certification (from CUMCS) so that we can commercially distribute our medical-grade cannabis products internationally,” VP of Agriculture Javier Franco stated in the Oct. 25 news release. “This further establishes our commitment to operational excellence and transparency, as well as our commitment to producing high-quality, consistent cannabis products to serve the global cannabis markets.” For more information, visit the company’s website at www.FloraGrowth.ca. NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://ibn.fm/FLGC

• Lexaria has embarked on its HYPER-H21-4 study, its fourth hypertension clinical study, and it’s most ambitious yet
• This study builds on the HYPER-H21-1 and HYPER-H21-2 findings, as well as the HYPER-H21-3 study that is set to begin dosing in mid-November 2021
• Lexaria’s goal is to pursue regulatory approval for its proprietary DehydraTECH-CBD for potential use as a treatment for high blood pressure
• Study protocols are being readied for submission to the IRB, and approval is expected by January 2022

Lexaria Bioscience (NASDAQ: LEXX) has, so far in 2021, embarked on several studies geared towards evaluating its proprietary DehydraTECH(TM) CBD for the potential treatment of hypertension and heart disease. Results from the first hypertension study, HYPER-H21-1, were released on July 29, 2021, showing that the administration of a single dose of 300 mg of DehydraTECH-CBD resulted in a significant reduction in blood pressure from baseline. Of the 24 adult volunteers in the study, those who were Stage 2 hypertensive, peak systolic blood pressure reductions from baseline were observed of as much as approximately 13 mmHg by the 50-minute time point with DehydraTECH-CBD. Additionally, systolic blood pressure remained depressed throughout almost the entire 3-hour duration of the study (https://ibn.fm/DENxV). The second study of the year, HYPER-H21-2, also yielded more impressive results. Again, 16 adult volunteers took part in the study, which involved taking three doses of 150 mg each of DehydraTECH-CBD, with results measured over a 24-hr ambulatory period. At selected times during the study, volunteers with mild to moderate hypertension averaged as much as a 20 mmHg decrease in blood pressure, relative to placebo, coupled with an average 7% reduction in systolic pressure. The learnings from these two studies have led up to the HYPER-H21-4 clinical study, Lexaria’s most ambitious one thus far. It is expected to involve 60 different volunteers aged between 45 and 70 years. Each of them will use three 150 mg doses of DehydraTECH-CBD every day over six weeks. “HYPER-H21-4 is the most ambitious study Lexaria has ever undertaken and is enabled from the successful outcomes from our other 2021 human hypertension studies,” noted Chris Bunka, Lexaria’s Chief Executive Officer (“CEO”). This study will use a double-blinded, randomized cross-over design while also utilizing a placebo control. A specific group of volunteers will already be using leading standard care hypertension drugs to evaluate the efficacy of the patented DehydraTECH technology, particularly, DehydraTECH-CBD with and without other hypertension treatments. The HYPER-H21-4 study will be more comprehensive than Lexaria’s previous studies. The eventual goal is to seek regulatory approvals for DehydraTECH-CBD for potential use as a treatment for high blood pressure, and data from this study could be instrumental in that pursuit. Different types of analysis will be conducted, from 24-hour ambulatory blood pressure to autonomic balance and arterial stiffness, brain structure and function through magnetic resonance imaging and blood biomarkers including lipids such as cholesterol and more. Study protocols for this study are being readied for submission to the Independent Review Board (“IRB”), and approval is expected by January 2022. In the meantime, Lexaria has completed DehydraTECH-CBD manufacturing for the HYPER-H21-3 study. Clinical test articles have also been delivered to the study location. Dosing is set to begin in mid-November or thereabouts and will be completed by mid-December. Blood pressure findings will be reportable by the end of January 2022 and will contribute to the HYPER-H21-4 study as well. Today, about 1.28 billion people suffer from hypertension, making it one of the world’s top health problems. Of these, only 21% of them have the condition under control, a statistic that demonstrates an enormous unmet need (https://ibn.fm/jUP1F). The hypertension treatment market is valued at USD$28 billion per year, and it is projected that in 2022, the broader cardiovascular disease category, under which hypertension falls, will be valued at USD$146 billion (https://ibn.fm/zVMT9). Lexaria understands the high unmet need for hypertension and cardiovascular diseases in general, hence its investment into its DehydraTECH research and the development of its proprietary DehydraTECH-CBD. With the HYPER-H21-4 study, the company is inching ever closer to regulatory approval, which would allow it to tap into this lucrative market and offer relief to billions of people living with cardiovascular diseases today. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

Metro Toronto Convention Center, North Building 255 Front St W The Lift & Co. Expo, Canada’s number one cannabis event, makes a comeback this year in Toronto. This four-day event promises to be better than ever before, all while educating, connecting, and growing cannabis consumers, professionals, and media. This event will feature over 250 exhibitors and different forward-thinking speakers, movers and shakers within the industry. It promises to offer attendees top-notch educational content, enrich thought leadership from the industry’s brightest minds, and present fun and authentic networking opportunities. The four-day event will have the Lift Cannabis Conference on the first day. This conference will be dedicated to Cannabis 2.0 updates, where Canada’s top business leaders, regulators, and innovators will share their perspectives on critical issues affecting Canada’s cannabis business sector. It promises value to new start-ups, those seeking to expand their businesses, or even curious consumers. There will be something for everyone. The second day will feature the Lift Psychedelics Business Summit along with the Lift Industry Day. The Industry Day will serve as an excellent avenue to kick-start in-depth conversations, build networks, spark relationships, create opportunities, and fuel collaborations. The Lift Psychedelics Business Summit, on the other hand, will take a deep dive into psychedelics research and the psychedelics industry. It is structured to offer attendees the most up-to-date business intelligence, specifically on the four pillars of today’s psychedelic renaissance. The last two days of the expo are dubbed “Consumer Days.” Lift & Co. invites all recreational consumers and medical patients to explore, learn and connect with over 250 different exhibitors from Canada and around the world. These consumer days will also feature speakers and panels on the main stage, covering the most talked about topics and answering frequently asked questions about the cannabis industry. Over 200 companies have confirmed their support of the event, which promises to be Canada’s largest industry and consumer cannabis event. Some include Cannabis Prospect Magazine, CAVCM, BioFloral, Indiva, Flush, and BIS Solutions. Thousands of cannabis enthusiasts and business people are also expected to attend in what will be an unmatched opportunity to build their brand awareness, explore global expansion opportunities, network, and engage with unique audiences. All roads lead to Toronto this November for Canada’s number one cannabis event. For those interested in the event, please purchase their tickets here https://ibn.fm/E1fZx Should you wish to exhibit at the event, you can book a booth here https://ibn.fm/6a1l3

• Pharmaceutical company Tryp Therapeutics is developing a proprietary synthetic hallucinogen as potential medical solutions for select unmet health needs, with a focus on taking psychedelic therapeutics beyond mental health
• The company recently attended the Wonderland: Miami where Compass Pathways unveiled highly anticipated data from their Phase 2b trial in treatment-resistant depression
• Tryp’s Chairman and CEO Greg McKee served on a panel at Wonderland: Miami discussing the potential of synthetic psilocybin in chronic pain indications and the importance of supporting industry wins

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) Chairman and CEO Greg McKee recently participated in Microdose’s Wonderland: Miami conference as a panelist for the “Developing Psychedelic Medicine Beyond What We Already Know” forum exploring the potential of once-taboo substances that are gaining an increasing measure of legitimacy and legal recognition. McKee’s appearance at the Nov. 8 and 9 event billed as “The Largest Psychedelic Medicine Business Event, Ever” gave Tryp an audience that was expected to include participants from a span of up to 140 countries or more in the Sun Belt’s “Magic City,” a world-class hub for trade and tourism. Greg gave an overview of Tryp’s strategy and progress, as well as addressing the crowd in a call to action to continue to emphasize strong support from every angle in order to give psychedelic therapeutic potential the validation it has already proven to deserve. The Compass data provided proof of rapid and durable responses after three weeks of psilocybin dosing and psychotherapy. Tryp has been actively engaged in developing synthetic psychedelic drugs as the newest sought-after solutions in treating chronic pain and other medical conditions with largely unmet needs. These data continue to validate Tryp’s hypothesis, as Tryp continues to progress towards conducting 4 Phase 2a trials evaluating psilocybin and psychotherapy in fibromyalgia, and eating disorder, pending a favorable review by the FDA. The company’s submission of an Investigational New Drug application to the U.S. Food and Drug Administration (“FDA”) for its TRP-8802 clinical candidate (https://ibn.fm/mz1Je) marks the latest advancement in its clinical trial that will initially evaluate 25mg oral psilocybin drug candidate, provided by Usona Institute. Compass Pathway’s data revealed the highest response rate among the 25mg dosing cohort, which provides further support for Tryp’s upcoming trial, and Tryp’s trademarked drug candidate, TRP-8803. TRP-8803 will be a synthetic psilocybin drug candidate in which the Company is completing preclinical and bridging studies to perfect its novel route of administration that will lead to more precise control over the patient’s psychedelic experience during the treatment. Tryp expects to complete a Phase 2a trial for TRP-8802 during the next nine months to determine its safety and initial effectiveness among patients with fibromyalgia. Similarly, TRP-8802 will be evaluated for its performance in treating phantom limb pain and complex regional pain syndrome (“CRPS”). Additional testing in select eating disorders is expected soon pending further review from the FDA. The clinical trials will be run in combination with psychotherapists trained by Fluence Training. The company has developed a novel method of administering TRP-8803 to make the experience better for patients. Although testing is still in the pre-clinical stage for it, Tryp expects to benefit from data produced in the TRP-8802 trials as well as data derived directly from TRP-8803 to advance it to phase 2b testing within the next 18 months and on to eventual commercialization. Tryp is committed to driving clinical progress and doing its part to continue to validate the use of psilocybin in select chronic diseases. For more information, visit the company’s website at www.TrypTherapeutics.com. NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF

• Ammonia is currently the second most produced chemical
• Its production, which accounts for 2% of the world’s fossil fuel use, currently generates over 420 million tons of CO2 annually
• With the growing global population, the demand for nitrogen for fertilizer is increasing, and with it comes an increase in CO2 production
• Ammonia supply out of the Black Sea region has dropped, with natural gas, the primary feedstock for ammonia production, expected to reach a long-time high of US$1,000/mt
• FuelPositive seeks to capitalize on the growing need for access to fertilizer and a dwindling ammonia supply chain with its on-site green ammonia production systems

According to the United Nations, the world population is projected to reach 9.8 billion in 2050, and 11.2 billion in 2100 (https://ibn.fm/yXNLi). This population growth will put a strain on global food supplies and productivity – but it will also significantly increase the global demand for nitrogen for fertilizer. While the farming sector has benefitted from innovations such as genetically-modified crops and AI-driven agriculture to boost crop yields, the primary need for most of the world is simply greater access to fertilizer as opposed to these other innovations. FuelPositive (TSX.V: NHHH) (OTCQB: NHHHF) has pioneered a clean energy solution in the form of green ammonia for various applications, including fertilizer for the agriculture sector. Ammonia’s chemical name is NH3. In the agriculture sector, it is primarily the “N” or nitrogen that plays a key role because it is necessary for the healthy growth of crops. But the “H”, which stands for hydrogen, is equally important. With its proprietary system, FuelPositive can store hydrogen in its green ammonia, allowing it to be efficiently used for energy storage and as fuel for internal combustion engine vehicles. When used properly, as fertilizer or as a fossil fuel replacement, the only discernable emissions from its carbon-free green ammonia is water vapor, or, in the case of fertilizer, some hydrogen emissions which are completely inert. (Nitrous oxide which is created when ammonia is burned, can be eliminated with proper combustion or by using catalytic convertors in internal combustion engines.) Most importantly, the use of FuelPositive’s green ammonia in agriculture will result in a significant reduction in CO2 emissions, a critical benefit, considering how food production contributes to global warming worldwide. Ammonia currently ranks as the second most produced chemical globally, with production accounting for 2% of the world’s fossil fuel use. The industry, as a whole, generates over 420 million tons of CO2 annually, creating a challenging tension between producing much-needed fertilizer to meet our needs for food and reducing carbon emissions (https://ibn.fm/T6chL). FuelPositive’s green ammonia technology provides an innovative solution to growing environmental concerns. It also addresses another important challenge: centralization of ammonia production. For most companies in this sector, operating at scale in massive centralized production facilities increases ammonia output, reducing the gap between supply and demand. However, this centralization results in a precarious supply chain buffeted by fossil fuel shortages, damage to facilities because of extreme weather and even labor shortages. The resulting drop in production and rise in prices causes food shortages, as well as economic hardship for farmers around the world. The Director of New Business Equipment at Mitsubishi Heavy Industries Compressor International Corporation (MCO-I), Clayton Jurica, has reckoned that the solution lies not in choosing larger or smaller plants. Instead, he notes, “There are pockets of demand around the world where transportation or logistics is complicated, so building small to mid-sized ammonia production plants to meet local demand makes economic sense.” FuelPositive’s green ammonia effectively addresses problems associated with scaling and transportation. It requires less energy to produce and is manufactured using a modular, scalable, transportable production system – a “plant in a box” – that is situated where the green ammonia is required. There is no need for massive refineries or a complicated supply chain. The end user simply produces the amount of green ammonia needed using air, water and sustainable electricity. In the case of farms, the farmer would have a FuelPositive production system on the farm, producing fertilizer for their crops, fuel for their farm systems and machinery, and to be used as on-the-farm grid storage for use when other sources of renewable electricity are unavailable. With the recent drop in ammonia supplies out of the Black Sea, FuelPositive’s green ammonia is even more appealing. As of the end of October 2021, delivery from Black Sea refineries into Europe was challenging, given how low gas supplies have become. Some of the trade sources are reportedly out of supply until mid-November, a factor that is driving up the price, which is expected to hit US$1,000 per metric tonne (“MT”) (https://ibn.fm/ksIiL). As it stands, natural gas and coal are the primary feedstocks for ammonia production. However, low pump rates in Russia have made the product even more scarce in the Black Sea, a factor that is further pushing up its price and inhibiting ammonia production in Europe. However, with FuelPositive’s green ammonia, reliance on large amounts of natural gas or coal in ammonia production is not a factor, allowing for a greener yet more reliable method of ammonia production. FuelPositive is looking to capitalize on this dwindling supply of ammonia to push its green alternative, making ammonia more accessible to farmers and contributing to a greener planet, while greatly growing its market share. For more information, visit the company’s website at www.FuelPositive.com. NOTE TO INVESTORS: The latest news and updates relating to NHHHF are available in the company’s newsroom at https://ibn.fm/NHHHF

• Red White & Bloom has officially entered Phase 2 of an aggressive three-phase expansion plan in Florida
• Phase 2 involves the installation and commissioning of 30 customized, self-contained growing pods
• RWB recently received OMMU approval for the first five pods that it subsequently installed and commissioned
• The company, through its Red White & Bloom Florida LLC subsidiary, produced the first batch of chocolates from the new Sanderson production facility, making substantial progress since launching the greenhouse facility in Apopka in late September

Following the early October completion of phase one of a three-phase development strategy that captures Red White & Bloom Brands’ (CSE: RWB) (OTCQX: RWBYF) expansion plan in Florida, the company has officially entered the second phase. This announcement follows the receipt of an Office of Medical Marijuana Use (“OMMU”) approval on October 22 that sanctioned the installation, commissioning, and loading of five of 30 planned modular grow pods. With the five approved pods already growing plants, RWB, through its subsidiary Red White & Bloom Florida LLC (“RWBFL”), is fast-tracking the remaining 25 pods with the expectation that they will be operational no later than the first of December. Combined, the 30 16’ by 40’ customized, self-contained pods will provide about 19,000 square feet of operating space. Each pod will be capable of producing 63 pounds of sellable product per harvest, while collectively, they are expected to produce 10,000 pounds of high-quality flower annually. RWB anticipates that the annual yield will generate $30 million in additional revenue. “The grow pods provide us with speed to market capabilities, which are needed for RWBFL to meet and exceed expectations for generating profitable revenue early in 2022,” commented Jim Frazier, GM of RWB Florida. According to Brad Rogers, Red White & Bloom CEO, the RWBFL team has been on time, on target, and under budget in executing each step of the development strategy for the two cultivation centers in Apopka and Sanderson. “Coupled with our cultivation and processing in Sanderson, the additional product [from the pods] will ensure Red White & Bloom has the needed inventory to fulfill inventory requirements at our HT Medical Cannabis dispensary in Springhill and for the next three dispensaries opening in the first quarter of 2022. The locations of the three dispensaries are St. Petersburg, Daytona, and Miami Beach,” Rogers continued. In addition to the activation of the five pods, RWB announced its subsidiary had achieved another milestone with the production of the first batch of chocolates from its new Sanderson production facility. Announced on September 9, the facility was built out to GMP specifications to capitalize on Florida’s burgeoning cannabis derivative market, which is expected to reach $2 billion in annual sales by 2025 from a projected $1.3 billion in 2021 (https://ibn.fm/0DTzt). RWB also reported that its subsidiary had made significant progress since launching the 45,000 square foot greenhouse in Apopka in late September (https://ibn.fm/NTeGX). Half of the greenhouse is utilized for auto flower production for biomass to support RWBFL’s extraction operation in the future. The remaining half is reserved for mother plants, clones, and vegetative operations for RWB’s proprietary genetic strains. Moreover, RWBFL has hired highly talented cultivation specialists to enable aggressive growth and fulfill a Q4 harvest schedule. By yearend, the subsidiary expects to have expanded its current team of 15 to 25 and then to 50 by the end of Q1 2021. Prospective employees can view job openings via https://ibn.fm/7OTPm. The three-phased development strategy aligns perfectly with Rogers’ summary of the company’s focus for the remainder of 2021 and throughout 2022 (https://ibn.fm/2A0IF). “The company will focus on the continued growth of our top-line revenue and bottom-line results through expansion of our house of brands that continue to gain momentum, fortification of our vertically integrated businesses, and the synergies from our M&A success,” stated Rogers. Notably, Phase 3, which is on schedule, will focus on increasing the cultivation capacity in Sanderson as well as building out the remaining space in Apopka to enable RWBFL to generate profitable revenue by maximizing the two facilities. For more information, visit the company’s website at www.RedWhiteBloom.com. NOTE TO INVESTORS: The latest news and updates relating to RWBYF are available in the company’s newsroom at https://ibn.fm/RWBYF

Date: November 16-18, 2021  Virtual Event Roth Capital Partners is proud to announce its 10th annual technology event: the Roth Technology and AgTech Answers Virtual Event.  Scheduled for November 16-18, 2021, the event is aimed at investors, offering them the chance to hear from and meet with executive management from private and public companies covering a range AgTech and Technology sub-sectors. This year’s event will be highlighted by virtual one-on-one/small group meetings, coupled with two industry panels. These small group discussions will be held throughout the 3-day event and primarily cover capital perspectives on AgTech. Leading investors in the sector will play an integral role in steering the discussions and offering insights and input into the industry dynamics for attendees. They will also be available for any questions that participants might have. The meetings will also feature 40-minute management-investor video conference calls. Here, clients will be offered extensive interaction with executive management to gain in-depth insights into a company of their interest. Additionally, the event’s two industry panels will discuss changemakers in agriculture today. Over 100 companies so far, including 22nd Century Group, AeroFarms and AgroFresh Solutions, Inc., have confirmed their participation in the event, sponsored by KPMG, Morrison Foerster and InvestorBrandNetwork (“IBN”). This year’s event reflects Roth’s overall theme and approach with its conferences. Featuring its signature format of Q&A sessions and one-on-one management meetings, it promises to offer value to attendees and help forge relationships designed to benefit the parties involved. In the past, Roth has held conferences covering various industries, from healthcare to energy and cannabis. This 10th annual technology event promises to be bigger and better than ever before. For those interested in the event visit https://ibn.fm/cwX4o, and see registration page at https://ibn.fm/kGo4C.

• Rich communication services (“RCS”) and big-data insights provider FingerMotion has seen revenue growth of 25 percent year-over-year in its mobile SMS and MMS services, according to recent quarterly financial analysis
• FingerMotion is beginning to record revenues in a third channel of operations thanks to its trademarked big data platform Sapientus, which is providing the foundation of an array of insurtech services
• China’s mobile payment use saw a sharp increase last year in response to the COVID pandemic and telecommunications products and services providers such as FingerMotion anticipate continued growth during the coming years
• China’s government is also encouraging development of its insurance industry services, providing optimism for continued demand for big data services such as Sapientus’ platform to help build the infrastructure

As mobile payments continue to inch their way upwards in China’s mature smartphone access market, communications technology solutions provider FingerMotion (OTCQX: FNGR) is building revenue growth and pursuing innovations to attract new users and increase engagement. FingerMotion noted in last month’s report on its Q2 financial position that quarterly growth in its SMS (texting) & MMS (phone photo, video and audio sharing) business revenue had hit 25 percent year over year. And growth in its Telecommunications Products and Services business revenue had reached 142 percent YOY. China’s population is expected to pass 750 million proximity mobile payment users (using a mobile phone to pay for goods or services while at a physical point-of-sale terminal) during the coming year and approach 800 million by 2025, with a gradual increase in the percentage of the globe-leading population doing so each year following a spike during the pandemic, according to Insider Intelligence analysts (https://ibn.fm/iKjms). The trend shows that mobile payments have become the country’s top payment method, especially in urban areas, according to Insider Intelligence. By 2025, around two-thirds of China’s consumers are expected to be using proximity mobile payments and peer-to-peer payments (“P2P”) as a regular course of business. FingerMotion expects to draw on the increased attention it has gained during consumers’ shift to increased digital traffic as a result of the COVID pandemic to continue building its user base, but the company is also turning its attention to the potential of its big data platform, Sapientus. Sapientus-related revenue has been in a nascent stage this year as the company develops its new services, but the appeal of the company’s unparalleled access to China’s consumers with over half a million transactions daily and its ability to readily draw on data to build the foundations of an insurtech industry have led to agreements such as the deal with global insurer Pacific Life to provide data for Pacific Life’s Re-insurance division. And the country’s government has encouraged further development of the insurance industry, as noted in the China Banking and Insurance Regulatory Commission’s recent statement encouraging an increase in services to gig-economy delivery workers, elderly people and children with congenital diseases and medical conditions (https://ibn.fm/kHyXc). That in turn is boosting expectations for big data revenue growth during the coming months. “This is the third consecutive quarter of Big Data revenues and we expect it to continue and eventually outpace our existing revenue streams,” CEO Martin Shen stated when last month’s report was released (https://ibn.fm/NKhr8). “This quarter was more of a transition to greater profitability as more of our initiatives started contributing to gross margin.” For more information, visit the company’s website at www.FingerMotion.com. NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at https://ibn.fm/FNGR

• The EMBARK program represents the broad spectrum of ways in which therapeutic benefits might be experienced
• Program offers psychedelic clinical trial facilitators foundational training to provide skillful, ethical care to participants receiving psychedelic treatment
• EMBARK is built around open architecture to support varieties of psychedelic experience within a coherent therapeutic framework

In a climate where psychedelic treatments are increasing in usage and acceptance, the importance of providing support and guidance in the space becomes even more important. With that in mind, Cybin (NEO: CYBN) (NYSE American: CYBN) has launched its proprietary EMBARK Psychedelic Facilitator Training Program (https://ibn.fm/3lzkp). Named for the program’s six clinical domains — Existential-Spiritual, Mindfulness, Body Aware, Affective-Cognitive, Relational, Keeping Momentum — the EMBARK program represents the broad spectrum of ways in which therapeutic benefits might be experienced in psychedelic treatment, as well as the equally broad training therapists need to facilitate the treatment. “Psychedelic medicines and the great healing potential they hold have only just begun to find their place in our culture and its array of therapeutic approaches,” explained Bill Brennan, a cocreator of the program. “EMBARK represents an important step forward in that process. “We designed it to be uniquely responsive to the distinctive and disruptive ways that these medicines heal people, while also able to incorporate synergistic aspects of other evidence-based treatments,” Brennan continued. “Its flexible, six-domain structure allows us to open the aperture on our notions of healing and expand our ability to help patients reach a place of wellness. We offer EMBARK in a spirit of service and deep respect for psychedelic medicines and the many avenues of healing they open to us.” Led by an expert team, the program offers psychedelic clinical trial facilitators the foundational training needed to provide skillful and ethical care to participants receiving psychedelic treatment. With an emphasis on experiential learning, the training will kick off with an in-person training retreat at the Whidbey Institute, a home for transformational learning in Washington state. The training includes an experiential training component, in addition to the core training and practice sessions on the EMBARK model. Cybin’s EMBARK Psychedelic Facilitator Training Program is designed to prepare facilitators to work within the program’s six domains. The program enhances each facilitator’s individual therapeutic training and expertise by offering a flexible curriculum that emphasizes trauma-informed, culturally competent, and ethically rigorous care. “We’re excited to host this training,” said Dr. Alex Belser, EMBARK’s coauthor and Cybin chief clinical officer. “When we first created EMBARK, we canvassed 20 different psychedelic-assisted psychotherapies. We found that some therapies left out important aspects, like people’s spiritual experiences, somatic experiences or human relationships. “Patients were telling us that these experiences were central to their healing, but many therapies seemed to be missing critical pieces,” Dr. Belser continued. “To address this challenge, we developed EMBARK, which provides an open architecture to support the varieties of psychedelic experience within a coherent therapeutic framework. This is a patient-centered approach for the whole person.” Cybin is focused on progressing psychedelic therapeutics, making it an ideal advocate and sponsor of the EMBARK approach. A leading biotechnology company, Cybin is working to progress psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. For more information, visit the company’s website at www.Cybin.com. NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN